Saturday, August 15, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,805
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,805 facts checked against source5,200 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Regeneron Pharmaceuticals, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Libtayo is the leading immunotherapy for non-melanoma skin cancers

    80% confidence

  • Regeneron has announced $7B+ in ongoing and planned domestic investments

    80% confidence

  • Dupixent has 1.4M+ active patients worldwide

    80% confidence

  • Regeneron has approximately 45 product candidates in clinical development

    80% confidence

  • Libtayo is first and only immunotherapy approved for high-risk adjuvant cutaneous squamous cell carcinoma

    80% confidence

  • EYLEA sales decline driven by competitive pressures, compounded bevacizumab market share loss due to patient affordability constraints, patient transition to EYLEA HD, and lower net selling price

    80% confidence

  • Dupixent is the most widely used innovative branded antibody medicine worldwide

    80% confidence

Data points we hold from this source

Sanofi · collaboration revenue5.9 billion_USD

Cited in these Via News reports

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results — Source | Via News | Via News